TRIAL DATA
Phase 2 study evaluates pembrolizumab combination for MSS/pMMR metastatic colorectal cancerA Phase II study tested pembrolizumab plus capecitabine and bevacizumab in microsatellite stable/mismatch repair-proficient metastatic colorectal cancer, a population that typically does not respond well to immunotherapy alone. (Clinical Colorectal Cancer)